Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Regeneron Pharmaceuticals
(NQ:
REGN
)
990.68
-7.55 (-0.76%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
34
35
Next >
Healthcare Sector Update: Life in the Slow Lane while we wait for BIOTECH Bounce
October 14, 2024
Healthcare sector lags despite moderate growth. Note bad news from CVS and Humana.
Via
Talk Markets
Here's How Much $100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth Today
October 10, 2024
Via
Benzinga
What the Options Market Tells Us About Regeneron Pharmaceuticals
October 10, 2024
Via
Benzinga
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
October 09, 2024
The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential...
Via
Benzinga
Inquiry Into Regeneron Pharmaceuticals's Competitor Dynamics In Biotechnology Industry
October 09, 2024
Via
Benzinga
A Closer Look at 24 Analyst Recommendations For Regeneron Pharmaceuticals
October 04, 2024
Via
Benzinga
Market Whales and Their Recent Bets on REGN Options
October 03, 2024
Via
Benzinga
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
October 03, 2024
Via
Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $400 Today
September 30, 2024
Via
Benzinga
Regeneron Chief Flags Health Risks with Popular Weight-Loss Medications Like Ozempic, Says Company Targets Muscle Preservation For Its Obesity Drugs
October 07, 2024
Regeneron's CSO George Yancopoulos warns that GLP-1 weight-loss drugs like Ozempic may lead to rapid muscle loss, increasing health risks. Regeneron is investigating therapies to offset these effects...
Via
Benzinga
Should You Buy the Dip on This Top Growth Stock?
October 05, 2024
The biotech needs to overcome an issue most drugmakers face at some point.
Via
The Motley Fool
Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?
September 29, 2024
10 worst performing large-cap stocks last week: SMMT, MMYT, MEDP, REGN, GPN, AFRM, SMCI, FTI, FCNCA, NOW. Are they in your portfolio?
Via
Benzinga
Stock Market Rally Hits Fresh Highs, Fueled By Micron Earnings, China Stimulus: Weekly Review
September 27, 2024
The S&P 500 hit record highs, fueled by Micron and Chinese stimulus.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
A Closer Look at Regeneron Pharmaceuticals's Options Market Dynamics
September 25, 2024
Via
Benzinga
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
September 25, 2024
Via
Benzinga
FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease
September 27, 2024
The FDA approved Regeneron and Sanofi's Dupixent as an add-on treatment for inadequately controlled COPD, demonstrating significant reductions in exacerbations and improved lung function in Phase 3...
Via
Benzinga
Exposures
Product Safety
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
September 27, 2024
The FDA signed off on Regeneron and Sanofi's Dupixent for patients with uncontrolled COPD.
Via
Investor's Business Daily
Exposures
Product Safety
Taiwan Semiconductor, American Tower, Trane Technologies And A Health Care Stock On CNBC's 'Final Trades'
September 26, 2024
Analyst Stephen Weiss of Short Hills Capital Partners said he still finds Taiwan Semiconductor Manufacturing Company cheap.
Via
Benzinga
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
September 25, 2024
Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna outperforming expectations in myasthenia gravis, offering less frequent...
Via
Benzinga
Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?
September 24, 2024
Regeneron filed an appeal after a court's decision, which was issued under seal.
Via
Benzinga
Smart Money Is Betting Big In REGN Options
September 23, 2024
Via
Benzinga
Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
September 11, 2024
Via
Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,000 Today
September 10, 2024
Via
Benzinga
This BP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
September 24, 2024
Via
Benzinga
Tesla Leads S&P 500 Index, While Biotech Giant Tumbles On Court Ruling
September 23, 2024
The EV giant, once a big S&P 500 laggard in 2024, is now up for the year.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea
September 23, 2024
Eylea is one of Regeneron's biggest moneymakers, and Amgen is looking to knock it off.
Via
Investor's Business Daily
Time To Invest And Or Trade In Bio-Tech Stocks?
September 13, 2024
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help...
Via
Talk Markets
Topics
ETFs
Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease
September 11, 2024
Regeneron and Sanofi's Dupixent achieves positive Phase 3 results for chronic spontaneous urticaria, meeting key endpoints.
Via
Benzinga
MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits
September 11, 2024
MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits
Via
News Direct
Prediction: These 2 Companies Will Split Their Stocks by 2027
September 11, 2024
Eli Lilly and Regeneron Pharmaceuticals are good stock-split candidates thanks to years of successes.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
34
35
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.